Guo, H., Ding, Q., Gong, Y., Gilcrease, M. Z., Zhao, M., Zhao, J., . . . Huo, L. (2020). Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res.
Chicago-tyylinen lähdeviittausGuo, Hua, et al. "Comparison of Three Scoring Methods Using the FDA-approved 22C3 Immunohistochemistry Assay to Evaluate PD-L1 Expression in Breast Cancer and Their Association With Clinicopathologic Factors." Breast Cancer Res 2020.
MLA-viiteGuo, Hua, et al. "Comparison of Three Scoring Methods Using the FDA-approved 22C3 Immunohistochemistry Assay to Evaluate PD-L1 Expression in Breast Cancer and Their Association With Clinicopathologic Factors." Breast Cancer Res 2020.